tiprankstipranks
Fulcrum Therapeutics Reports Q3 2024 Financial Progress
PremiumCompany AnnouncementsFulcrum Therapeutics Reports Q3 2024 Financial Progress
3M ago
Fulcrum Therapeutics reports Q3 EPS (35c), consensus (41c)
Premium
The Fly
Fulcrum Therapeutics reports Q3 EPS (35c), consensus (41c)
3M ago
Fulcrum Therapeutics expects cash to fund operations into at least 2027
Premium
The Fly
Fulcrum Therapeutics expects cash to fund operations into at least 2027
3M ago
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
5M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
5M ago
Goldman Sachs moves to Not Rated on Fulcrum Therapeutics after study failure
Premium
The Fly
Goldman Sachs moves to Not Rated on Fulcrum Therapeutics after study failure
5M ago
Leerink gives Fulcrum fourth downgrade after study failure
PremiumThe FlyLeerink gives Fulcrum fourth downgrade after study failure
5M ago
Fulcrum Therapeutics downgraded to Market Perform from Outperform at Leerink
Premium
The Fly
Fulcrum Therapeutics downgraded to Market Perform from Outperform at Leerink
5M ago
Fulcrum Therapeutics downgraded to Underperform from Neutral at BofA
Premium
The Fly
Fulcrum Therapeutics downgraded to Underperform from Neutral at BofA
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100